Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anthem, Inc. stock logo
ANTX
Anthem
$4.69
-3.3%
$3.45
$1.00
$6.91
$174.58M-0.95328,847 shs317,556 shs
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
$3.23
+2.2%
$0.00
$1.08
$9.08
$179.03M1.44655,562 shs227,439 shs
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
$1.34
+8.1%
$2.99
$0.15
$1.27
$61.85M-0.4314.23 million shs28,860 shs
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
$4.21
+1.2%
$3.71
$1.53
$4.48
$205.62M0.7218,371 shs112,589 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anthem, Inc. stock logo
ANTX
Anthem
0.00%-2.50%+44.18%+327.01%+285.19%
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
0.00%-2.42%-0.92%+322,999,900.00%+322,999,900.00%
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
0.00%0.00%+4.69%-22.09%-61.71%
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
0.00%-4.09%+13.68%+38.54%+398,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anthem, Inc. stock logo
ANTX
Anthem
$4.69
-3.3%
$3.45
$1.00
$6.91
$174.58M-0.95328,847 shs317,556 shs
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
$3.23
+2.2%
$0.00
$1.08
$9.08
$179.03M1.44655,562 shs227,439 shs
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
$1.34
+8.1%
$2.99
$0.15
$1.27
$61.85M-0.4314.23 million shs28,860 shs
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
$4.21
+1.2%
$3.71
$1.53
$4.48
$205.62M0.7218,371 shs112,589 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anthem, Inc. stock logo
ANTX
Anthem
0.00%-2.50%+44.18%+327.01%+285.19%
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
0.00%-2.42%-0.92%+322,999,900.00%+322,999,900.00%
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
0.00%0.00%+4.69%-22.09%-61.71%
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
0.00%-4.09%+13.68%+38.54%+398,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anthem, Inc. stock logo
ANTX
Anthem
1.00
SellN/AN/A
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
1.00
SellN/AN/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
0.00
N/AN/AN/A
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
2.50
Moderate Buy$7.0066.27% Upside

Current Analyst Ratings Breakdown

Latest RTTR, WHWK, CNTN, and ANTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2026
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
Initiated CoverageOutperform
4/16/2026
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
Initiated CoverageMarket Outperform$8.00
4/7/2026
Anthem, Inc. stock logo
ANTX
Anthem
Initiated CoverageSell (D-)
3/27/2026
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
Reiterated RatingSell (D-)
3/9/2026
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
Initiated CoverageSell (E+)
2/5/2026
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
Initiated CoverageOutperform$6.00
(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anthem, Inc. stock logo
ANTX
Anthem
N/AN/AN/AN/A$1.94 per shareN/A
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
N/AN/AN/AN/A$10.92 per shareN/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
N/AN/AN/AN/A$0.10 per shareN/A
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
$7.14M29.15N/AN/A$2.89 per share1.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anthem, Inc. stock logo
ANTX
Anthem
-$35.17M-$1.16N/AN/AN/AN/A-55.04%-49.13%N/A
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
-$35.92M-$3.99N/AN/AN/AN/A-35.59%-27.05%N/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
-$10.13MN/AN/AN/AN/AN/AN/A-162.05%N/A
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
-$20.60M$0.478.96N/AN/AN/A-62.88%-58.98%N/A

Latest RTTR, WHWK, CNTN, and ANTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/31/2026Q4 2025
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
N/A$0.54N/A$0.54N/AN/A
3/17/2026Q4 2025
Anthem, Inc. stock logo
ANTX
Anthem
N/A-$0.29N/A-$0.29N/AN/A
3/12/2026Q4 2025
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
-$0.55-$0.34+$0.21-$0.34N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Anthem, Inc. stock logo
ANTX
Anthem
N/AN/AN/AN/AN/A
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
N/AN/AN/AN/AN/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
N/AN/AN/AN/AN/A
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anthem, Inc. stock logo
ANTX
Anthem
N/A
6.87
6.87
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
N/A
5.29
5.29
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
N/A
3.67
3.67
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
N/A
10.26
10.26

Institutional Ownership

CompanyInstitutional Ownership
Anthem, Inc. stock logo
ANTX
Anthem
90.47%
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
1.16%
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
0.84%
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
52.08%

Insider Ownership

CompanyInsider Ownership
Anthem, Inc. stock logo
ANTX
Anthem
20.79%
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
6.70%
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
15.40%
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
49.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anthem, Inc. stock logo
ANTX
Anthem
N/A36.00 million28.51 millionNot Optionable
Hillstream Biopharma Inc. stock logo
CNTN
Hillstream Biopharma
256.66 million52.86 millionN/A
Ritter Pharmaceuticals Inc stock logo
RTTR
Ritter Pharmaceuticals
746.15 millionN/ANot Optionable
Whitehawk Therapeutics, Inc. stock logo
WHWK
Whitehawk Therapeutics
2149.43 million24.76 millionN/A

Recent News About These Companies

Whitehawk Therapeutics Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anthem stock logo

Anthem NASDAQ:ANTX

$4.69 -0.16 (-3.30%)
Closing price 04:00 PM Eastern
Extended Trading
$4.50 -0.19 (-4.05%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Hillstream Biopharma stock logo

Hillstream Biopharma NASDAQ:CNTN

$3.23 +0.07 (+2.22%)
Closing price 04:00 PM Eastern
Extended Trading
$3.24 +0.01 (+0.43%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.

Ritter Pharmaceuticals stock logo

Ritter Pharmaceuticals NASDAQ:RTTR

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Whitehawk Therapeutics stock logo

Whitehawk Therapeutics NASDAQ:WHWK

$4.21 +0.05 (+1.20%)
Closing price 04:00 PM Eastern
Extended Trading
$4.20 0.00 (-0.12%)
As of 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.